GW Pharmaceuticals KGV 2024

GW Pharmaceuticals Aktienanalyse

Šta radi GW Pharmaceuticals?

GW Pharmaceuticals PLC is a British company that has been involved in the development and manufacturing of prescription medications based on cannabis since 1998. The company is a global leader in the research of medical cannabis and is headquartered in Cambridge. The history of GW Pharmaceuticals traces back to the founding of the company by Dr. Geoffrey Guy, who focused on the medical use of cannabis. In its early years, the company focused on developing medicinal cannabis strains with high levels of cannabinoids, such as THC or CBD. A pivotal moment for the company was the approval of Sativex in 2010, a medication for the treatment of spastic symptoms in multiple sclerosis. This was the first cannabis-based medication to be approved by a regulatory authority. Since then, GW Pharmaceuticals has expanded its portfolio of products and is involved in various areas, including the treatment of epilepsy, autism, pain, insomnia, and cancer. The company has several medications in late-stage clinical development and plans to bring more medications to the market. GW Pharmaceuticals' business model is based on researching, manufacturing, and selling medical cannabis. The company is an innovative pioneer in this field and works closely with health authorities and medical professionals to ensure the safety and efficacy of its products. GW Pharmaceuticals operates in several sectors, including the development of medical cannabis, the manufacturing of medications, and collaboration with health authorities and medical professionals. The company strives to develop high-quality and safe products that improve patients' quality of life. One of GW Pharmaceuticals' key products is Epidiolex, a medication for the treatment of severe forms of epilepsy in children. The medication contains CBD, one of the compounds found in medical cannabis, and has been approved by the U.S. Food and Drug Administration (FDA). Another important product of GW Pharmaceuticals is Sativex, a spray for the treatment of spastic symptoms in multiple sclerosis. The medication contains a combination of THC and CBD and is approved in several countries. GW Pharmaceuticals also has products in the pipeline targeting the treatment of autism, pain, insomnia, and cancer. The company is committed to advancing the use of medical cannabis and its compounds in medical practice and contributing to the improvement of health. Overall, GW Pharmaceuticals has made a significant contribution to the research and development of medical cannabis and has established itself as a leader in this field. The company is dedicated to developing high-quality medications that improve patients' lives and contribute to improving health. GW Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

KGV у детаљу

Otključavanje KGV-a kompanije GW Pharmaceuticals

Kurs-Gewinn-Verhältnis (KGV) kompanije GW Pharmaceuticals je ključni pokazatelj koji investitori i analitičari koriste za određivanje tržišne vrednosti preduzeća u odnosu na njegovu dobit. Izračunava se deljenjem trenutne cene akcije sa dobiti po akciji (EPS). Viši KGV može ukazivati na to da investitori očekuju veći budući rast, dok niži KGV može ukazivati na potencijalno potcenjenu kompaniju ili niža očekivanja rasta.

Godišnja uporedba

Procena KGV-a kompanije GW Pharmaceuticals na godišnjem nivou pruža uvid u trendove vrednovanja i raspoloženje investitora. Rastući KGV tokom godina signalizira rastuće poverenje investitora i očekivanja u pogledu budućeg rasta dobiti, dok padajući KGV može odražavati zabrinutost u pogledu profitabilnosti ili izgleda za rast kompanije.

Utjecaj na investicije

KGV kompanije GW Pharmaceuticals je ključni faktor za investitore koji žele da izvaguju rizik i povrat. Temeljna analiza ovog odnosa, zajedno s drugim finansijskim pokazateljima, pomaže investitorima da donesu obrazložene odluke o kupovini, držanju ili prodaji akcija kompanije.

Tumačenje fluktuacija KGV-a

Promene u KGV-u kompanije GW Pharmaceuticals mogu biti rezultat različitih faktora, uključujući promene u dobiti, kretanja cene akcije i promene očekivanja investitora. Razumevanje osnovnih razloga ovih fluktuacija je od suštinskog značaja za predviđanje buduće performanse akcija i procenu unutrašnje vrednosti preduzeća.

Često postavljana pitanja o GW Pharmaceuticals akciji

Koje je odnos cene i zarade akcija od GW Pharmaceuticals?

Odnos cene i dobiti akcija GW Pharmaceuticals trenutno iznosi 2,72.

Kako se odnos cene i zarade akcija GW Pharmaceuticals promenio u poređenju sa prošlom godinom?

Odnošaj cene i zarade kompanije GW Pharmaceuticals u poređenju sa prošlom godinom porastao je za 0% porastao.

Koje posledice visok odnos cene i zarade ima za investitore?

Visok odnos cene i dobiti ukazuje na to da su akcije kompanije relativno skupe i da investitori možda ostvare manji prinos.

Šta znači nizak odnos cene i zarade?

Nisko odnos cene i zarade znači da je akcija kompanije relativno jeftina i investitori mogu potencijalno ostvariti viši prinos.

Da li je odnos cene i dobiti akcija kompanije GW Pharmaceuticals visok u poređenju sa drugim kompanijama?

Da, odnos cene i zarade (P/E) kompanije GW Pharmaceuticals je visok u poređenju sa drugim kompanijama.

Kako povećanje odnosa cene i zarade od GW Pharmaceuticals utiče na kompaniju?

Povećanje odnosa cena-dobit od GW Pharmaceuticals bi dovelo do veće tržišne kapitalizacije preduzeća, što bi pak dovelo do veće procene vrednosti preduzeća.

Kako smanjenje odnosa cene i zarade od GW Pharmaceuticals utiče na kompaniju?

Smanjenje odnosa cene i zarade od GW Pharmaceuticals dovelo bi do niže tržišne kapitalizacije kompanije, što bi zauzvrat dovelo do niže vrednosti preduzeća.

Koji su neki faktori koji utiču na odnos cene i zarade od GW Pharmaceuticals?

Neki faktori koji utiču na odnos cene i zarade GW Pharmaceuticals su rast kompanije, finansijska situacija kompanije, razvoj industrije i opšta ekonomska klima.

Kolika je dividenda koju isplaćuje GW Pharmaceuticals?

U poslednjih 12 meseci, GW Pharmaceuticals je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, GW Pharmaceuticals će verovatno isplatiti dividendu od 0 USD.

Kolika je dividendna prinosa za GW Pharmaceuticals?

Dividendski prinos od GW Pharmaceuticals trenutno iznosi .

Kada GW Pharmaceuticals isplaćuje dividendu?

GW Pharmaceuticals isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Koliko je sigurna dividenda od GW Pharmaceuticals?

GW Pharmaceuticals je isplaćivao dividendu svake godine u poslednjih 0 godina.

Kolika je dividenda kompanije GW Pharmaceuticals?

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

U kom sektoru se nalazi GW Pharmaceuticals?

GW Pharmaceuticals se svrstava u sektor 'Zdravlje'.

Wann musste ich die Aktien von GW Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

Da biste primili poslednju dividendu od GW Pharmaceuticals od 2. 6. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 2. 6. 2024..

Kada je GW Pharmaceuticals poslednji put isplatio dividendu?

Isplata poslednje dividende izvršena je 2. 6. 2024..

Kolika je bila dividenda od GW Pharmaceuticals u godini 2023?

U godini 2023 kompanija GW Pharmaceuticals je isplatila 0 USD kao dividende.

U kojoj valuti GW Pharmaceuticals isplaćuje dividendu?

Dividende od GW Pharmaceuticals se isplaćuju u USD.